Alkylphospholipids – A Promising Class of Chemotherapeutic Agents with a Broad Pharmacological Spectrum

Abstract

-PURPOSE:Since when alkylphospholipds (ALPs) were discovered and, even further after miltefosine's approval for the treatment of cutaneous metastasis of breast cancer and leishmaniasis, their activity against many other diseases have been extensively studied. This review aims to provide a summary of the alkylphospholipids' applications investigated so far. RESULTS: The mechanism of action of ALPs is not fully understood, however it is believed that they interfere with lipid homeostasis leading to cell apoptosis. Due to ALPs cytotoxic activity, this class of molecules has shown to be effective against many diseases and conditions. Besides the approval of miltefosine for application in cutaneous metastasis of breast cancer and visceral and cutaneous leishmaniasis, several other analogs have proved efficacy and are promising as less toxic alternatives. ALPs have also shown in vitro and in vivo activity against Trypanosoma spp., amoebae, Tricomonas vaginalis, Schistosoma mansoni, HIV, and some fungi and bacteria species. The use of ALPs for intraocular lens coating is also under investigation. In addition, a clinical trial comparing miltefosine with usual treatments to spontaneous urticaria is also being conducted. CONCLUSIONS: Alkylphospholipids present such a broad pharmacological spectrum that justifies the need for further investigations of the drug class mechanisms of action, as well as the search for new analogs with improved activity and toxicological profiles.

Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)

“…Cells treated with edelfosine exhibited a marked and rapid decrease in p-Akt Ser473 levels, coupled with a reduction in the phosphorylation levels of mTOR (p-mTOR) ( 95 ). Its clinical use is limited by the high toxicity and low selectivity ( 96 ). The thioether analog of edelfosine, ilmofosine (BM 41.440) has demonstrated dose-dependent in vivo and in vitro antitumor activity in various solid tumor models.…”

Epidemiological, clinical and laboratory aspects of human visceral leishmaniasis (HVL) associated with human immunodeficiency virus (HIV) coinfection: a systematic review

“…In a review study, Cota et al (de Almeida Pachioni et al , 2013) reported that, according to available data, there was a higher mortality rate among patients treated with Sb v than in those treated with amphotericin B. In the countries of Ethiopia, India and Spain, liposomal amphotericin B was the drug used to treat 605 (65%) coinfected patients, with the lowest number, 149 (16%), of the use of Sb v or miltefosine, 143 (15%).…”

An Overview of Drug Resistance in Protozoal Diseases

“…MT inhibits the biosynthesis of phosphatidylcholine, thus affecting phospholipid biosynthesis [79,103]. The proposed mechanism of action firstly involves the binding to cell membrane, followed by the internalization through two membrane proteins: L. donovani miltefosine transporter ( Ld MT), a member of the P4-ATPase subfamily; and a potential noncatalytic β subunit of Ld MT ( Ld Ros3) [97,104].…”